Literature DB >> 7511202

The impact of obesity, fat distribution, and energy restriction on insulin-like growth factor-1 (IGF-1), IGF-binding protein-3, insulin, and growth hormone.

M H Rasmussen1, J Frystyk, T Andersen, L Breum, J S Christiansen, J Hilsted.   

Abstract

The aim of this study was to characterize the association between serum insulin-like growth factor-1 (IGF-1) and obesity, as well as fat distribution, before and during moderate energy restriction (1,200 kcal/d). In 51 females and nine males having a body mass index (BMI) between 27 and 39 kg/m2, relationships between serum IGF-1, IGF-binding protein-3 (IGFBP-3), insulin, growth hormone (GH), blood glucose, and anthropometric measurements of body fat were examined. The patients were studied before treatment and again after 8 and 16 weeks of dieting. Visceral adipose tissue (AT) was estimated by anthropometric computed tomography (CT)-calibrated equations. In females, IGF-1 was inversely associated with the abdominal sagittal diameter (SagD) and with the visceral AT (r = -.41, P = .006). No significant correlations were found between IGF-1 and BMI or other indices of adiposity. Weight loss caused a temporary increase in IGF-1 concentrations (P = .03) and continued decrements in blood glucose levels (P = .0004 at 16 weeks). A statistically significant inverse correlation between IGF-1 and blood glucose levels was present before (r = -.30, P = .02) and after 8 (r = -.37, P = .007) and 16 (r = .02, P = .02) weeks of dietary treatment. Both serum IGF-1 and insulin levels were positively correlated with serum IGFBP-3 levels (r = .34, P = .009 and r = .34, P = .008, respectively). We conclude that IGF-1 levels in obese females reflect the intraabdominal fat mass rather than obesity per se. IGF-1 and blood glucose levels are inversely correlated in obesity before and during energy restriction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511202     DOI: 10.1016/0026-0495(94)90099-x

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  26 in total

1.  Failure of IGF-I and IGFBP-3 to diagnose growth hormone insufficiency.

Authors:  H Mitchell; M T Dattani; V Nanduri; P C Hindmarsh; M A Preece; C G Brook
Journal:  Arch Dis Child       Date:  1999-05       Impact factor: 3.791

2.  Altered metabolism and resistance to obesity in long-lived mice producing reduced levels of IGF-I.

Authors:  Adam B Salmon; Chad Lerner; Yuji Ikeno; Susan M Motch Perrine; Roger McCarter; Christian Sell
Journal:  Am J Physiol Endocrinol Metab       Date:  2015-02-03       Impact factor: 4.310

3.  Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.

Authors:  C Invitti; L Fatti; M G Camboni; L Porcu; L Danesi; G Delitala; F Cavagnini
Journal:  J Endocrinol Invest       Date:  1996-09       Impact factor: 4.256

4.  Parity-induced decrease in systemic growth hormone alters mammary gland signaling: a potential role in pregnancy protection from breast cancer.

Authors:  Robert K Dearth; David A Delgado; Jill K Hiney; Thushangi Pathiraja; Steffi Oesterreich; Dan Medina; W Les Dees; Adrian V Lee
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-09

5.  Necdin-E2F4 interaction provides insulin-sensitizing effect after weight loss induced by gastric bypass surgery.

Authors:  Zehra N Pamuklar; Jiegen Chen; Michael Muehlbauer; Anna Spagnoli; Alfonso Torquati
Journal:  Surg Obes Relat Dis       Date:  2011-11-07       Impact factor: 4.734

6.  Epidemiologic survey: reference ranges of serum insulin-like growth factor 1 levels in Caucasian adult population with immunoradiometric assay.

Authors:  Fahri Bayram; Vedia Tonyukuk Gedik; Özgür Demir; Ahmet Kaya; Kürşat Gündoğan; Rıfat Emral; Ahmet Öztürk; Ali Rıza Uysal; Demet Çorapçıoğlu
Journal:  Endocrine       Date:  2011-05-03       Impact factor: 3.633

Review 7.  The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes.

Authors:  Swapnil N Rajpathak; Marc J Gunter; Judith Wylie-Rosett; Gloria Y F Ho; Robert C Kaplan; Radhika Muzumdar; Thomas E Rohan; Howard D Strickler
Journal:  Diabetes Metab Res Rev       Date:  2009-01       Impact factor: 4.876

8.  A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance.

Authors:  Christopher B Newgard; Jie An; James R Bain; Michael J Muehlbauer; Robert D Stevens; Lillian F Lien; Andrea M Haqq; Svati H Shah; Michelle Arlotto; Cris A Slentz; James Rochon; Dianne Gallup; Olga Ilkayeva; Brett R Wenner; William S Yancy; Howard Eisenson; Gerald Musante; Richard S Surwit; David S Millington; Mark D Butler; Laura P Svetkey
Journal:  Cell Metab       Date:  2009-04       Impact factor: 27.287

9.  Insulin-like growth factor-I is inversely related to adiposity in overweight Latino children.

Authors:  Claudia M Toledo-Corral; Christian K Roberts; Gabriel Q Shaibi; Christianne J Lane; Paul B Higgins; Jaimie N Davis; Marc J Weigensberg; Michael I Goran
Journal:  J Pediatr Endocrinol Metab       Date:  2008-09       Impact factor: 1.634

Review 10.  Mechanisms underlying the neuroendocrine response to physical exercise.

Authors:  A Leal-Cerro; A Gippini; M J Amaya; M Lage; J A Mato; C Dieguez; F F Casanueva
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.